What You Should Know:
- Brixton Biosciences, a clinical-stage life sciences company focused on innovative pain treatments raises $33M in Series B funding led by Schooner Capital with participation from SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures.
- In addition, Brixton has bolstered its leadership team. Dr. Michael Fishman, a renowned pain management specialist, joins as Chief Medical Officer. Additionally,
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Flatiron & ACCC Partner to Expand Community Oncology Clinical Trials
What You Should Know:
- Flatiron Health, an oncology-focused healthtech company, and the Association of Cancer Care Centers (ACCC), a powerful network of cancer care professionals, are proud to announce a new collaboration.
- The partnership aims to make cancer clinical trials more accessible to patients in community settings and empower healthcare providers with cutting-edge data capture technology.
Boosting Clinical Trial Participation
ACCC boasts over 40,000 members
Read More
Enable Injections, Roche Expand Partnership to Advance Wearable Drug Delivery
- Enable Injections, Inc. ("Enable"), a leader in wearable drug delivery technology, today announced an expanded partnership with Roche.
- The collaboration leverages Enable's expertise in the enFuse® platform to accelerate the development and commercialization of innovative treatment options.
EnFuse Technology: Revolutionizing Drug Delivery
The enFuse platform is a groundbreaking wearable device designed for:
Subcutaneous Delivery of Large Volumes: Unlike traditional methods,
Read More
BMF Biotechnology Launches 3D Printed Organ-On-A-Chip Platform to Accelerate Life Sciences Research
What You Should Know;
- Boston Micro Fabrication (BMF) today announced the launch of BMF Biotechnology Inc., a dedicated subsidiary focused on developing and commercializing innovative BioChips – advanced microfluidic platforms that mimic human organs.
- By leveraging BioChip technology, BMF Biotechnology aims to accelerate breakthroughs in drug development, improve cosmetic safety and efficacy testing, and ultimately, contribute to the development of more effective treatments
Read More
ARTBIO, Nucleus RadioPharma Partner to Advance Targeted Alpha Radioligand Therapies for Cancer
What You Should Know:
- ARTBIO, Inc., a leader in developing targeted alpha radioligand therapies (ARTs) for cancer, and Nucleus RadioPharma Inc., a pioneer in radiopharmaceutical development and manufacturing, announced today a strategic collaboration to propel ARTBIO's clinical trials forward.
Nucleus to Manufacture ARTBIO's Lead Therapy Candidate
This agreement signifies a significant step for ARTBIO. Nucleus will manufacture ARTBIO's 212Pb-radiolabeled therapies for its
Read More
Every Cure and BioPhy Partner to Repurpose Existing Drugs Faster with AI
What You Should Know:
- BioPhy, an AI drug development company, and Every Cure, a non-profit dedicated to unlocking the potential of existing drugs for new uses, today announced a strategic partnership to revolutionize drug repurposing through artificial intelligence (AI).
- The partnership follows Every Cure's recent funding from the Advanced Research Projects Agency for Health (ARPA-H). A successful pilot using AI led to the identification of potential treatments for diseases like sickle
Read More
Faster Drug Discovery: Yseop & AWS Unveils GenAI Tool for Biopharma R&D
What You Should Know:
· Yseop, a world-leading Artificial Intelligence (AI) software company and pioneer in Generative AI, has announced today the development of an enhanced Generative AI application tailored for the Biopharma industry, with support from Amazon Web Services (AWS).
· A member of the AWS Partner Network (APN), Yseop has strategically utilized AWS since its inception, leveraging its robust security and scalability to
Read More
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis
What You Should Know:
- Quest Diagnostics today announced it will acquire key assets of PathAI Diagnostics, including its state-of-the-art digital pathology laboratory in Memphis, Tennessee.
- As part of the acquisition, this facility will become Quest's AI and digital R&D center, supporting its pathology businesses, AmeriPath, and Dermpath Diagnostics.
Digital Pathology and AI Integration
Quest will license PathAI's AISight™ digital pathology system and AI
Read More
G1 Therapeutics and Pepper Bio Ink Global License Agreement for Lerociclib
What You Should Know:
- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding the Asia-Pacific region) for lerociclib for all indications outside acute radiation syndrome (ARS).
- As Pepper Bio’s first in-licensed therapeutic, lerociclib is a potent and selective
Read More
Genomics plc & GSK Partner to Optimize Clinical Trials with Genetic Risk Testing
What You Should Know:
- Genomics plc, a leader in polygenic risk score (PRS) technology, and pharmaceutical giant GSK inks a new collaboration to explore the potential of PRS for optimizing clinical trial design.
- The innovative approach could revolutionize the way researchers select patients and ultimately lead to faster development of new treatments.
Unlocking the Power of Genetics for Clinical Trials
Genomics plc brings its expertise in PRS technology to the table.
Read More
